

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 99,134-E)

In the Application of:


Jun Yuan et al.

Serial No. 09/914,957

International Application No. PCT/US00/06371

International Filing Date: March 10, 2000

For: Aryl Fused 2,4-Disubstituted Pyridines:
NK3 Receptor Ligands



Art Unit: 1614

RECEIVED
OCT 30 2002
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

BOX IDS

**Commissioner for Patents
Washington, D.C. 20231**

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the references cited below are enclosed. These references are also listed on the enclosed PTO Form 1449.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative relevance between references, whether cited in this or prior statements. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Foreign Documents

1. Giardina, et al., WO 97/19926, published June 5, 1997.

Other Documents


2. Giardina, et al., (1999) *IL FARMACO*, 54:364-374.

In accordance with MPEP Sections 609 and 707.05(b), it is requested the document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

Date: October 24, 2002

Respectfully Submitted,

By:


Steven J. Sarussi
Reg. No. 32,784

McDonnell, Boehnen Hulbert & Berghoff
300 South Wacker Drive
Chicago, IL 60606

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

99-134-F

Serial No.

09/914,957



INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

Yuan et al.

Filing Date:

Match 10, 2000

Group:

1614

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	1.	WO 97/19926	June 5, 1997					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	2.	Giardina, et al., (1999) <i>IL FARMACO</i> , 54:364-374.					
EXAMINER				DATE CONSIDERED			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

RECEIVED
OCT 30 2002
TECH CENTER 1600/2900